AGF Investments LLC lowered its stake in Edwards Lifesciences Corp (NYSE:EW) by 19.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,978 shares of the medical research company’s stock after selling 723 shares during the period. AGF Investments LLC’s holdings in Edwards Lifesciences were worth $562,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Nvwm LLC grew its position in Edwards Lifesciences by 6.8% in the first quarter. Nvwm LLC now owns 2,838 shares of the medical research company’s stock valued at $535,000 after acquiring an additional 181 shares during the last quarter. Commerce Bank grew its position in Edwards Lifesciences by 14.5% in the first quarter. Commerce Bank now owns 12,135 shares of the medical research company’s stock valued at $2,289,000 after acquiring an additional 1,538 shares during the last quarter. William Blair Investment Management LLC grew its position in Edwards Lifesciences by 2.2% in the first quarter. William Blair Investment Management LLC now owns 231,683 shares of the medical research company’s stock valued at $43,700,000 after acquiring an additional 5,012 shares during the last quarter. Hancock Whitney Corp grew its position in Edwards Lifesciences by 0.4% in the first quarter. Hancock Whitney Corp now owns 79,029 shares of the medical research company’s stock valued at $14,906,000 after acquiring an additional 276 shares during the last quarter. Finally, Fiera Capital Corp grew its position in Edwards Lifesciences by 90.6% in the first quarter. Fiera Capital Corp now owns 13,781 shares of the medical research company’s stock valued at $2,600,000 after acquiring an additional 6,549 shares during the last quarter. Institutional investors own 81.22% of the company’s stock.
A number of research firms have issued reports on EW. Wells Fargo & Co cut Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $250.00 to $230.00 in a research report on Tuesday, April 28th. Goldman Sachs Group assumed coverage on Edwards Lifesciences in a research note on Wednesday, February 12th. They set a “neutral” rating and a $253.00 price target on the stock. Canaccord Genuity reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, April 24th. Morgan Stanley lifted their price target on Edwards Lifesciences from $241.00 to $250.00 and gave the company an “overweight” rating in a research note on Friday, April 24th. Finally, BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, April 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $247.52.
In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 3,470 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $217.53, for a total value of $754,829.10. Following the transaction, the vice president now directly owns 45,288 shares of the company’s stock, valued at $9,851,498.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Larry L. Wood sold 3,566 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $207.00, for a total value of $738,162.00. Following the completion of the transaction, the vice president now directly owns 120,995 shares in the company, valued at $25,045,965. The disclosure for this sale can be found here. Over the last three months, insiders sold 95,878 shares of company stock worth $20,047,408. Insiders own 1.48% of the company’s stock.
Edwards Lifesciences stock opened at $218.81 on Friday. The stock’s 50 day moving average is $212.94 and its 200 day moving average is $222.43. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.36 and a quick ratio of 2.47. The firm has a market cap of $45.13 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.75 and a beta of 0.85. Edwards Lifesciences Corp has a one year low of $154.52 and a one year high of $247.64.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $1.51 EPS for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.22. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the firm earned $1.32 earnings per share. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Corp will post 4.95 earnings per share for the current fiscal year.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.